Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, appointed Philip Vickers, President, and Chief Executive Officer. Vickers succeeds David Donabedian, co-founder, and start-up CEO of the company. Vickers has more than 30 years of experience in the biopharma industry. As CEO, he will play an instrumental role in the company’s work to eliminate cells that drive disease in areas of high unmet medical need through the continued development...